SHARPE
Reported results
- Q1 revenue increased 6% to $1.4 billion, or up 7% on a core constant currency basis.
- GAAP diluted earnings per share increased 23% to $2.92.
- Non-GAAP diluted earnings per share increased 14% to $2.91.
- GAAP gross margin was 61.5%, while non-GAAP gross margin increased 50 basis points to 62.5%.
- GAAP income from operations was $453 million and non-GAAP income from operations was $506 million.
- Operating cash flow was $422 million and free cash flow was $374 million.
Guidance
- FY 2027 Core Constant Currency revenue growth: 5 - 7%
- FY 2027 Reported revenue: $5.75 - $5.85 Billion
- FY 2027 Non-GAAP Diluted EPS: $12.00 - $12.25
Notes
During the first quarter of fiscal year 2027, Resmed revised the presentation of restructuring expenses and amortization of acquired intangibles, reclassifying prior-period amounts to conform to the current-period presentation.
Price and volatility reaction
The stock moved -9.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -10.3 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 252.83 | 2026-10-29 |
| Close after release | 229.94 | 2026-10-30 |
| Realised move | -9.1% | close to close |
| 30d ATM IV change | -10.3 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.